Welcome to our dedicated page for Immunome SEC filings (Ticker: IMNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunome, Inc. (IMNM) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other registered offerings. These documents are central for understanding how a clinical-stage targeted oncology company like Immunome describes its pipeline, clinical data and capital raising activities to regulators and investors.
Immunome’s recent Form 8-K filings cover several important topics. One 8-K details positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, the company’s investigational oral gamma secretase inhibitor for progressing desmoid tumors, including the primary endpoint in progression-free survival and key secondary endpoints. The same filing discusses safety findings and the company’s stated plan to submit a New Drug Application for varegacestat to the U.S. Food and Drug Administration.
Other 8-Ks address financial and capital markets events, such as a follow-on public offering of common stock under an effective shelf registration statement on Form S-3, including the number of shares, public offering price and underwriters. Additional current reports reference quarterly financial results, business updates, and the furnishing of investor presentations that describe Immunome’s pipeline, including IM-1021, IM-3050 and preclinical ADC programs built around the HC74 TOP1 inhibitor payload.
Through this page, users can review how Immunome characterizes the design and potential attributes of its HC74 payload, summarizes preclinical data, and outlines risks and forward-looking statements in its regulatory language. Stock Titan enhances access to these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify clinical milestones, financing terms, and strategic disclosures without manually parsing every section.
Immunome Inc. Chief Scientific Officer Jack Higgins sold 9,438 shares of common stock at $21.64 per share on April 2, 2026 in an open-market transaction. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 19, 2025, indicating it was scheduled in advance. Following the sale, Higgins directly holds 22,000 shares of Immunome common stock. He is also listed as custodian for three separate 1,000-share accounts for his children under the Uniform Transfer to Minors Act, but he disclaims beneficial ownership of those custodial shares, which are subject to a lockup agreement dated December 15, 2025.
Immunome Inc. Chief Financial Officer Max Rosett exercised stock options to acquire 71,561 shares of common stock on April 2, 2026, at exercise prices of $1.05 and $1.35 per share. These options were fully vested and had original expiration dates in 2032 and 2033.
On the same day, Rosett sold a total of 65,000 Immunome shares in open-market transactions at weighted average prices of $21.91 and $22.48 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly owned 54,037 shares of Immunome common stock.
IMNM submitted a Form 144/A notifying the proposed sale of 65,000 shares of Common Stock to be executed through Fidelity Brokerage Services LLC on 04/02/2026 on NASDAQ. The filing lists total value $1,425,084.64 and identifies prior acquisition reasons including stock option exercise (09/19/2024), an option grant (03/23/2023), and a merger payout (10/02/2023).
IMNM submitted a Rule 144 notice regarding proposed sales of common stock. The filing lists 65,000 and $4,723,550.00 alongside an NASDAQ designation and the date 04/02/2026. The excerpt also records earlier transactions tied to specific dates: 09/19/2024 (Stock Option Exercise, 27,620), 03/23/2023 (Option Granted, 17,524) and 10/02/2023 (Merger Payout, 19,856).
The issuer IMNM submitted a Form 144 notice related to proposed sales of Common Stock. The filing lists a proposed sale tied to a stock option exercise of 6,318 shares dated 08/15/2024 and a separate stock option exercise of 3,120 shares dated 03/27/2025. The broker listed is Fidelity Brokerage Services LLC. The filing date shown in the excerpt is 04/02/2026.
Immunome Inc. Chief Scientific Officer Jack Higgins reported a bona fide gift of 6,291 shares of Common Stock. The gift, coded as a disposition, carried a price of $0.00 per share. Following this transfer, he directly holds 31,438 shares of Immunome Common Stock.
The filing also lists indirect holdings of 1,000 shares of Common Stock in each of three custodial accounts for his children, recorded under the Uniform Transfer to Minors Act. Higgins disclaims beneficial ownership of these custodial shares, which are subject to a lockup agreement he entered into on December 15, 2025.
Immunome Inc. President and CEO Clay B. Siegall bought 25,450 shares of Common Stock in an open-market purchase. The transaction occurred on March 27, 2026 at a weighted average price of $19.67 per share, within a price range of $19.63 to $19.70.
Following this purchase, his direct holdings increased to 690,704 shares of Immunome Common Stock.
Immunome Inc: The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting that it beneficially owns 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment on 01/12/2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries will report holdings separately.
Immunome Inc. director Philip Wagenheim sold shares of Common Stock in two open-market transactions. He sold 36,800 shares on March 20, 2026 at a weighted average price of $20.47 per share and 28,200 shares on March 23, 2026 at a weighted average price of $20.65 per share. After these sales, he directly owns 341,147 shares of Immunome Common Stock.